Cargando…

Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression

BACKGROUND: Mesothelial E- and P-selectins substantially mediate the intraperitoneal spread of Pancreatic ductal adenocarcinoma (PDA) cells in xenograft models. In the absence of selectins in the host, the integrin subunit alpha-V (ITGAV, CD51) was upregulated in the remaining metastatic deposits. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Kemper, Marius, Schiecke, Alina, Maar, Hanna, Nikulin, Sergey, Poloznikov, Andrey, Galatenko, Vladimir, Tachezy, Michael, Gebauer, Florian, Lange, Tobias, Riecken, Kristoffer, Tonevitsky, Alexander, Aigner, Achim, Izbicki, Jakob, Schumacher, Udo, Wicklein, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235815/
https://www.ncbi.nlm.nih.gov/pubmed/34174926
http://dx.doi.org/10.1186/s13046-021-01946-2
_version_ 1783714406992969728
author Kemper, Marius
Schiecke, Alina
Maar, Hanna
Nikulin, Sergey
Poloznikov, Andrey
Galatenko, Vladimir
Tachezy, Michael
Gebauer, Florian
Lange, Tobias
Riecken, Kristoffer
Tonevitsky, Alexander
Aigner, Achim
Izbicki, Jakob
Schumacher, Udo
Wicklein, Daniel
author_facet Kemper, Marius
Schiecke, Alina
Maar, Hanna
Nikulin, Sergey
Poloznikov, Andrey
Galatenko, Vladimir
Tachezy, Michael
Gebauer, Florian
Lange, Tobias
Riecken, Kristoffer
Tonevitsky, Alexander
Aigner, Achim
Izbicki, Jakob
Schumacher, Udo
Wicklein, Daniel
author_sort Kemper, Marius
collection PubMed
description BACKGROUND: Mesothelial E- and P-selectins substantially mediate the intraperitoneal spread of Pancreatic ductal adenocarcinoma (PDA) cells in xenograft models. In the absence of selectins in the host, the integrin subunit alpha-V (ITGAV, CD51) was upregulated in the remaining metastatic deposits. Here we present the first experimental study to investigate if ITGAV plays a functional role in PDA tumor growth and progression with a particular focus on intraperitoneal carcinomatosis. METHODS: Knockdown of ITGAV was generated using an RNA interference-mediated approach in two PDA cell lines. Tumor growth, intraperitoneal and distant metastasis were analyzed in a xenograft model. Cell lines were characterized in vitro. Gene expression of the xenograft tumors was analyzed. Patient samples were histologically classified and associations to survival were evaluated. RESULTS: The knockdown of ITGAV in PDA cells strongly reduces primary tumor growth, peritoneal carcinomatosis and spontaneous pulmonary metastasis. ITGAV activates latent TGF-β and thereby drives epithelial-mesenchymal transition. Combined depletion of ITGAV on the tumor cells and E- and P-selectins in the tumor-host synergistically almost abolishes intraperitoneal spread. Accordingly, high expression of ITGAV in PDA cells was associated with reduced survival in patients. CONCLUSION: Combined depletion of ITGAV in PDA cells and E- and P-selectins in host mice massively suppresses intraperitoneal carcinomatosis of PDA cells xenografted into immunodeficient mice, confirming the hypothesis of a partly redundant adhesion cascade of metastasizing cancer cells. Our data strongly encourage developing novel therapeutic approaches for the combined targeting of E- and P-selectins and ITGAV in PDA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-021-01946-2.
format Online
Article
Text
id pubmed-8235815
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82358152021-06-28 Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression Kemper, Marius Schiecke, Alina Maar, Hanna Nikulin, Sergey Poloznikov, Andrey Galatenko, Vladimir Tachezy, Michael Gebauer, Florian Lange, Tobias Riecken, Kristoffer Tonevitsky, Alexander Aigner, Achim Izbicki, Jakob Schumacher, Udo Wicklein, Daniel J Exp Clin Cancer Res Research BACKGROUND: Mesothelial E- and P-selectins substantially mediate the intraperitoneal spread of Pancreatic ductal adenocarcinoma (PDA) cells in xenograft models. In the absence of selectins in the host, the integrin subunit alpha-V (ITGAV, CD51) was upregulated in the remaining metastatic deposits. Here we present the first experimental study to investigate if ITGAV plays a functional role in PDA tumor growth and progression with a particular focus on intraperitoneal carcinomatosis. METHODS: Knockdown of ITGAV was generated using an RNA interference-mediated approach in two PDA cell lines. Tumor growth, intraperitoneal and distant metastasis were analyzed in a xenograft model. Cell lines were characterized in vitro. Gene expression of the xenograft tumors was analyzed. Patient samples were histologically classified and associations to survival were evaluated. RESULTS: The knockdown of ITGAV in PDA cells strongly reduces primary tumor growth, peritoneal carcinomatosis and spontaneous pulmonary metastasis. ITGAV activates latent TGF-β and thereby drives epithelial-mesenchymal transition. Combined depletion of ITGAV on the tumor cells and E- and P-selectins in the tumor-host synergistically almost abolishes intraperitoneal spread. Accordingly, high expression of ITGAV in PDA cells was associated with reduced survival in patients. CONCLUSION: Combined depletion of ITGAV in PDA cells and E- and P-selectins in host mice massively suppresses intraperitoneal carcinomatosis of PDA cells xenografted into immunodeficient mice, confirming the hypothesis of a partly redundant adhesion cascade of metastasizing cancer cells. Our data strongly encourage developing novel therapeutic approaches for the combined targeting of E- and P-selectins and ITGAV in PDA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-021-01946-2. BioMed Central 2021-06-26 /pmc/articles/PMC8235815/ /pubmed/34174926 http://dx.doi.org/10.1186/s13046-021-01946-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kemper, Marius
Schiecke, Alina
Maar, Hanna
Nikulin, Sergey
Poloznikov, Andrey
Galatenko, Vladimir
Tachezy, Michael
Gebauer, Florian
Lange, Tobias
Riecken, Kristoffer
Tonevitsky, Alexander
Aigner, Achim
Izbicki, Jakob
Schumacher, Udo
Wicklein, Daniel
Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression
title Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression
title_full Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression
title_fullStr Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression
title_full_unstemmed Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression
title_short Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression
title_sort integrin alpha-v is an important driver in pancreatic adenocarcinoma progression
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235815/
https://www.ncbi.nlm.nih.gov/pubmed/34174926
http://dx.doi.org/10.1186/s13046-021-01946-2
work_keys_str_mv AT kempermarius integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression
AT schieckealina integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression
AT maarhanna integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression
AT nikulinsergey integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression
AT poloznikovandrey integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression
AT galatenkovladimir integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression
AT tachezymichael integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression
AT gebauerflorian integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression
AT langetobias integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression
AT rieckenkristoffer integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression
AT tonevitskyalexander integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression
AT aignerachim integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression
AT izbickijakob integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression
AT schumacherudo integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression
AT wickleindaniel integrinalphavisanimportantdriverinpancreaticadenocarcinomaprogression